Abbonarsi

Is the Charlson comorbidity index a good predictor of mortality and adverse effects in proximal humerus fractures? - 31/03/19

Doi : 10.1016/j.otsr.2018.11.016 
Ana Belén Fernández-Cortiñas a, b, , Jesús Vidal Campos c , Xavier Paredes-Carnero d , Fernando Marco Martinez e
a Department of Orthopaedic Surgery, Complutense University of Madrid, Madrid, Spain 
b Cosaga Hospital and Complexo Hospitalario Universitario de Ourense, Ourense, Spain 
c Department of Orthopaedic Surgery and Traumatology, El Carmen Hospital and Complexo Hospitalario Universitario de Ourense, Ourense, Spain 
d Department of Orthopaedic Surgery, Cosaga Hospital and Complexo Hospitalario Universitario de Ourense, Ourense, Spain 
e Shoulder and Elbow Unit, Department of Orthopaedic Surgery and Traumatology, Clínico San Carlos Hospital, Complutense University of Madrid, Madrid, Spain 

Corresponding author. Carmen Legisima, 7, 4° A., 32003 Ourense, Spain.Carmen Legisima, 7, 4° A.Ourense32003Spain

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Introduction

Proximal humerus fractures (PHF) are frequent in elderly patients. This population also suffers from a series of associated comorbidities, and PHF increases morbidity and mortality. The Charlson Comorbidity Index (CCI) is a tool used for calculating comorbidity and therefore the mortality risk.

Hypothesis

Our hypothesis is that CCI is a good predictor of mortality in patients suffering from PHF, and that there is a relationship between CCI and the development of adverse events.

Patients and methods

A retrospective study with prospective data collection of 354 patients who had been diagnosed and treated for a single PHF between August 1st, 2013 and July 31st, 2015 was carried out at our hospital. The minimum follow-up was 24 months (mean 51.1 months). This study included all patients regardless the severity of the fracture, the treatment performed (surgical or conservative treatment) or whether the patient had been admitted to the hospital or was treated as an outpatient. Adverse effects and mortality data were collected and the CCI was calculated.

Results

Patients with high CCI (>5) had a higher mortality risk 4.6 (95% CI [2.4–9.0]) compared to those with CCI<5. During follow-up, 40 (11%) patients died, being the mean follow-up of the patients overall 4.3 years 95% CI [4.1–4.4]. Patients suffering from systemic complications had a higher CCI average (p=0.001) compared to those who did not present adverse effects (HR=6.6; 95% CI [3.5–12.4]). No statistically significant relationship between the type of fracture (p=0.473) and mortality was found.

Conclusion

In our study CCI has proven to be a good predictor of mortality and there is a relationship between CCI and the development of adverse effects in patients suffering from PHF, which maybe should be taken into consideration in our therapeutic decision making.

Level of evidence

IV, retrospective observational study.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Proximal humerus fractures, Comorbidity, Charlson comorbidity index, Adverse effects, Mortality


Mappa


© 2018  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 105 - N° 2

P. 301-305 - aprile 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • Can objective criteria for poor tolerance of proximal humerus malunion be identified?
  • Aude Griffart, Pauline Joly-Monrigal, Julien Andrin, Cyril Lazerges, Michel Chammas, Bertrand Coulet
| Articolo seguente Articolo seguente
  • Deltoid-split approach versus deltopectoral approach for proximal humerus fractures: A systematic review and meta-analysis
  • Linzhen Xie, Yingying Zhang, Chunhui Chen, Wenhao Zheng, Hua Chen, Leyi Cai

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.